The aim of the present experiments was to determine the role of insulin and glucagon in the regulation of basal glucose production in dogs fasted overnight. A deficiency of either or both pancreatic hormones was achieved by infusin somatostatin (1 mug/kg per min), a potent inhibitor of both insulin and glucagon secretion, alone or in combination with intraportal replacement infusions of either pancreatic hormone. Infusion of somatostatin alone caused the arterial levels of insulin and glucagon to drop rapidly by 72+/-6 and 81+/-8%, respectively. Intraportal infusion of insulin and glucagon at rates of 400 muU/kg per min and 1 ng/kg per min, respectively, resulted in the maintenance of the basal levels of each hormone. Glucose production was measured using tracer (primed constant infusion of [3-3H]glucose) and arteriovenous difference techniques. Isolated glucagon deficiency resulted in a 35+/-5% (P less than 0.05) rapid and sustained decrease in glucose production which was abolished upon restoration of the plasma glucagon level. Isolated insulin deficiency resulted in a 52+/-16% (P less than 0.01) increase in the rate of glucose production which was abolished when the insulin level was restored. Somatostatin had no effect on glucose production when the changes in the pancreatic hormone levels which it normally induces were prevented by simultaneous intraportal infusion of both insulin and glucagon. A B S T R A C T The aim of the present experiments was to determine the role of insulin and glucagon in the regulation of basal glucose production in dogs fasted overnight. A deficiency of either or both pancreatic hormones was achieved by infusing somatostatin (1 ug/kg per min), a potent inhibitor of both insulin and glucagon secretion, alone or in combination with intraportal replacement infusions of either pancreatic hormone. Infusion of somatostatin alone caused the arterial levels of insulin and glucagon to drop rapidly by 72+6 and 81±8%, respectively. Intraportal infusion of insulin and glucagon at rates of400 ,uU/kg per min and 1 ng/kg per min, respectively, resulted in the maintenance of the basal levels of each hormone. Glucose production was measured using tracer (primed constant infusion of [3-3H]glucose) and arteriovenous difference techniques.
A B S T R A C T The aim of the present experiments was to determine the role of insulin and glucagon in the regulation of basal glucose production in dogs fasted overnight. A deficiency of either or both pancreatic hormones was achieved by infusing somatostatin (1 ug/kg per min), a potent inhibitor of both insulin and glucagon secretion, alone or in combination with intraportal replacement infusions of either pancreatic hormone. Infusion of somatostatin alone caused the arterial levels of insulin and glucagon to drop rapidly by 72+6 and 81±8%, respectively. Intraportal infusion of insulin and glucagon at rates of400 ,uU/kg per min and 1 ng/kg per min, respectively, resulted in the maintenance of the basal levels of each hormone. Glucose production was measured using tracer (primed constant infusion of [3-3H] glucose) and arteriovenous difference techniques.
Isolated glucagon deficiency resulted in a 35+5% (P < 0.05) rapid and sustained decrease in glucose production which was abolished upon restoration ofthe plasma glucagon level. Isolated insulin deficiency resulted in a 52+16% (P < 0.01) increase in the rate of glucose production which was abolished when the insulin level was restored. Somatostatin had no effect on glucose production when the changes in the pancreatic hormone levels which it normally induces were prevented by simultaneous intraportal infusion of both insulin and glucagon.
In conclusion, in the anesthetized dog fasted over-INTRODUCTION The ability of glucagon to increase hepatic glucose production has been well documented both in vivo (1) (2) (3) and in vitro (4, 5) . Similarly, the inhibitory action of insulin on glucose output has been clearly established (6) (7) (8) (9) (10) . Recent studies with isolated rat liver cells (11) and perfused rat livers (12) (13) (14) have suggested, in fact, that the two hormones interact to regulate hepatic glucose metabolism. This concept has proved more difficult to establish in vivo because of the potent glucoregulatory feedback loops which exist in the whole animal.
Assessment of the role of basal amounts of insulin and glucagon in the regulation of basal glucose production has proved even more difficult, not only because of the counterregulatory changes which ensue after perturbation of the level of either hormone, but also because it has been difficult to totally inhibit glucagon secretion. Glucagon, immunologically identical to pancreatic glucagon, has now been shown to be present in the gastrointestinal tract of various species (15, 16) , most notably the dog (17) . For this reason, even pancreatectomy has often been ineffective in creating glucagon deficiency (18) (19) (20) . Somatostatin, a hypothalamic growth hormone release inhibiting factor, has been shown to inhibit the secretion of insulin and glucagon both in vivo The Journal of Clinical Investigation Volume 58 December 1976 -1407- 1418 1407 (21) (22) (23) (24) and in vitro (25, 26) . This peptide has been
shown not onlv to inhibit the secretioni of glutcagon by the pancreas but also the release of gluicagoni from the gtut (27) . Its meechanism of actioni remcainis unelear btit may involve modification of calciumil fluix (25, 28, 29) and or cyclic nucleotide levels (30, 31 Eaclh dog wvas studiedl under sodium pentobarbital anesthesia (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) mg/kg i.v.) after an overnight fast (14-16 h ).
An endotracheal tube was inserted immediately after induction of the anesthesia and the animal was ventilated at a rate of 12-14 respirations per min with a tidal volume of 400 ml.
Angiocaths (14 gauge) were inserted percutaneously into the left jugular, cephalic, and saphenous vein to allow infusion of cardiogreen, [3-3H] glucose, and somatostatin, respectively. A small cut-down was performed over the left inguinal area to isolate the femoral artery which was also cannulated with a 14-gauge aingiocath. The right jugular vein was exposed by a small cut down and a radio-opaque catheter \vas guided through it into the major left hepatic vein where its tip was located 3-4 cm from the wedge position. Continuous infusion of heparin-saline (0.02 U/mIl; 0.5 ml/min) maintained the patency of the hepatic vein catheter. The femoral artery and the hepatic vein catheters, as well as the previously inserted portal vein catheter, were used for blood sampling. At the end of each experiment the patency and location of all catheter tips was verified.
Upon completion of the cannulations the dog was draped with a heating blanket to maintain a constant body temperature. Blood pressure, pulse rate, rectal temperature, Po2, Pco2, pH, and hematocrit were monitored at 30-min intervals throughout the study to confirm the stability of each preparation and to ensure adequate ventilation. per min) and(or) insulin (400 ,tU/kg per min). Insulin or glucagon replacement was considered adequate when the resulting arterial hormone concentration did not differ by more than 20% (approximately +3 ,uU/ml for insulin and +20 pg/ml for glucagon from its control period mean value. 16 of 20 dogs in which replacement of one or both pancreatic hormones was attempted met the above criteria, the results from experiments conducted on the four dogs in which replacement was inadequate were not included. In these animals the usual replacement doses were inappropriate and the resulting hormone levels did not match those ofthe control period.
Five different types of experiments were performed: (a) saline infusion, to assess the stabilitv of the animals; (b) somatostatin infusion, to study the effects of combined insulin and glucagon deficiency; (c) somatostatin plus intraportal insulini replacement, to assess the effects of glucagon deficiency; (d) somatostatin pltus intraportal glucagon replacement, to study the effects of insulin deficiency; and (e) somatostatin plus intraportal insulin and glucagon replacement, to examine the influence of the nonpancreatic effects of somatostatin on the observed changes. Samples were drawn every 10 min throughout each experiment.
Processing ofblood sample. The collection and imImediate processing of blood samples have been described previously (32) . Equivaleint aliquots of the infusate tracer solution were added to 5 ml of the dog's plasma (drawn immediately before the experiment) and to 5 ml of distilled water (saturated with benzoic acid and containing 100 mg/100 ml glucose) to monitor the recovery of glucose. Two aliquots of each solution were then run with the samples and the counts obtained were compared to those expected. Recovery varied from 92-98%. Glucose was isolated with the aid of cationic and anionic exchange resins. Radioactive water was removecl from the glucose samples by overnight evaporation in a vacuum oven at 60°C. Such treatment did not result in a loss of the [3-3H] (1, 36) has now been validated for both inulin (39) and glucose (40) and has been shown to yield accurate measurements over a wide range of deviations from steady state (39, 40) .
Glucose production was also calculated by the arteriovenous (A-V) difference technique. This method involves calculation of hepatic blood flow by using cardiogreen as described previously (32, 35) and determination of the glucose difference across the liver. The latter was accomplished knowing the portal, arterial, and hepatic vein whole blood glucose concentrations and assuming that 70% of the hepatic blood flow is derived from the portal vein (41) . The product of blood flow and the A-V difference represents net hepatic glucose production. Statistical analyses were carried out with the Student t test and the paired t test (42) .
RESULTS
Saline infusion. Fig. 1 14- glucose production or utilization. All measured parameters were stable throughout the experiment with the exception of insulin which declined slightly during the control period.
Somatostatin infusion. Fig. 2 illustrates the mean data from seven experiments in which somatostatin produced a concurrent deficiency of both pancreatic hormones. Arterial glucagon dropped by 72% to a mean level of 38 pg/ml, while insulin declined by 81% to a mean concentration of less than 5 ,U/ml. Portal vein IRI and IRG levels declined by 88 and 81%, respectively, reaching levels similar to those found in arterial plasma (Table I) . These hormonal changes were associated with a significant (P < 0.01) and sustained decrease (average drop of 40+5%) in the rate of glucose production (Table II, Fig. 2 ). Since the rate of glucose utilization exceeded the rate of glucose production after initiation of the somatostatin infusion, the plasma glucose level began to fall. Eventually, however, the two rates became synchronous and the plasma glucose level plateaued. Glucose utilization fell as a result of both insulin lack and the lower glucose level (i.e. mass effect). Fig. 2 also demonstrates that the hormone concentrations were rapidly reestablished when the somatostatin infusion was terminated. Recovery of glucagon occurred more rapidly than that of insulin and these changes were associated with a tripling of the rate of glucose production and a rapid rebound in the glucose level.
Glucagon deficiency. Fig. 3 illustrates the conisequences of isolated glucagon deficiency which was produced when somatostatin was given concurrently with an intraportal infusion of insulin. Insulin replacement prevented the somatostatin-induced drop in the IRI concentration and maintained the arterial insulin level at 13+1 ,uU/ml. Maintenance of the insulin level is also reflected in the portal vein IRI concentrations (39±+6 ,uU/ml; Table I ). The plasma glucagon concentration, on the other hand, declined rapidly, reaching a mean level of 31 pglml in arterial plasma (Fig. 3) .
As in the case of a deficiency of both pancreatic hormones, glucose production fell in a rapid and sustained manner (average drop of 35+5%; P < 0.01; Table III; Fig. 3 ). The plasma glucose concentration and the rate of glucose utilization also fell, as in the previou.s protocol. In this case, however, the fall in glucose utilization was slightly less and was entirely attributable to the decreasing glucose concentration. Upon cessation of the somatostatin and insulin infusions the glucagon concentration rebounded, while the insulin level remained relatively unchanged. The sudden increase in the glucagon level was associated with a normalization of the rate of glucose production and an increase in the plasma glucose concentration.
Insulin deficiency. Fig. 4 illustrates the mean data from experiments in which a specific insulin deficiency was created by giving somatostatin simultaneously with an intraportal glucagon infusion. Glucagon replacement prevented the somatostatin-induced drop in the IRG concentration and resulted in the maintenance of the arterial glucagon level at 113+22 pg/ml. Portal IRG levels also remained relatively unchanged (208+16 pg/ml; Table I level of less than 5 uU/ml (Fig. 4) . in the observed responses. The success of hoirnonal replacement is evident from the finding that the mean glucagon concentration measured in arterial plasma during the control period (average 111+5 pg/ml) was similar to that observed during the glucagon infusion period (average 117+2 pg/ml). In addition, the mean plasma insulin concentrations were similar during the FIGURE 4 The effects of somatostatin infusion (1 ,ug/kg per min) combined with intraportal glucagon replacement (1 ng/kg per min) on arterial plasma IRI and IRG levels and on the production, utilization, and concentration of plasma glucose in normal dogs. Values are means±SEM. Glucose turnover was measured isotopicallv. two periods (19±+1 and 17+2,uU/ml, respectively).
Hormonal replacement was also adequate when judged by portal vein values (Table I) . When the effect of somatostatin on the pancreatic hormone levels was prevented, it had no significant effect on the rate of glucose production (Table III the underproduction of glucose associated with glucagon deficiency and the overproduction of glucose associated with insulin deficiency. The rate of glucose utilization also remained unaltered during the infusion of somatostatin when the effect of the latter on the pancreatic hormone levels was prevented and consequently normoglycemia was maintained. The small increase in glucose production which occurred after cessation of the hormone and somatostatin infusions was primarily the result of responses in two animals (nos. 24 and 25). In both cases the increased production of glucose was associated with an excessive rebound of glucagon which followed a slight decline in the glucose level during the hormone infusion period.
Role of the pancreatic hormones. In Fig. 6 the results of the present experiments are used to illustrate the approximate role each pancreatic hormone plays in the maintenance of hepatic glucose production in the anesthetized overnight fasted dog. One can conclude that at least one-third of basal glucose production Regulation of was attributable to the presence of basal amounts of glucagon. Such basal levels ofglucagon, however, were capable of stimulating about three times as much glucose production when a deficiency of insulin was apparent. The potent inhibitory effect of insulin on glucose production was thus clearly demonstrated.
Since the insulin and glucagon levels apparently did not fall to zero in response to somatostatin, it should be pointed out that a total absence of either hormone might have resulted in a somewhat greater dependence of glucose production on basal glucagon. Comparison of glucose production by isotopic and hepatic A-V difference methods. Fig. 7 shows that the overproduction or underproduction of glucose associated with insulin or glucagon deficiency, respectively, were equally apparent whether a tracer or A-V technique was used to assess glucose production. Hepatic glucose output (determined by the A-V difference method) was slightly less than total glucose production (computed with isotopic data) in the control period of almost all experiments in which both techGlucose Production by Insulin and Glucagon niques were used. The percent of changes resulting from hormone perturbation, on the other hand, were somewhat larger when measured by the A-V difference technique. Glucagon deficiency was associated with an average drop of 47% in hepatic glucose output and insulin deficiency resulted in an average increase of 71% in hepatic glucose production.
While the antagonistic effects of insulin and glucagon on glucose production have long been recognized, the quantitative aspects of their interaction after an ovemight fast has not previously been defined. The present experiments demonstrate that glucagon plays a significant role in maintaining hepatic glucose production in the overnight fasted dog and that insulin acts as a potent antagonist to its action. The rate of glucose production in the postabsorptive state thus seems to reflect the balance between the stimulatory effect of glucagon and the inhibitory effect of insulin. It is the interplay between the two pancreatic hormones which is, at least in part, responsible for the regulation of glucose output by the liver.
In the majority of the present experiments, glucose production was measured by both a tracer technique and an A-V difference method. [3-3H] Glucose was used as the tracer molecule to allow accurate assessment of the rate of glucose production (43, 44) . Since the 3H atom in position three of glucose is lost to body water and cannot recirculate (43, 45) its use eliminates the underestimation which might otherwise result from recycling of the label (2). The absence of recirculation in the present experiments was confirmed by the lack of either [3H]alanine or [3H]lactate in plasma even after four h of [3-3H] glucose infusion. The overestimate of glucose production which can arise due to loss of label as the result offutile cycling (44) is also negligible when [3-3H] glucose is used as the isotope (43, 44) . The accuracy of the tracer determined glucose production rates (total glucose production) in the present set of experiments is supported by the finding that they were very similar to those calculated from data obtained with the A-V difference technique (net hepatic glucose production). The difference between the rates calculated using the two methods could be accounted for by a small amount of extrahepatic (kidney) glucose production (46) , by slight hepatic glucose uptake or by a combination of the two. It seems unlikely that hepatic glucose uptake would explain the small difference, however, since it has been reported that 14C label does not accumulate in glycogen even after prolonged infusion of 14C glucose into postabsorptive dogs (47) . In the present study the basal rates of glucose production were similar in all experimental groups and were in accord with previously published data (2, 48, 49) . The rate of glucose utilization was also normal in each group and was equivalent to the rate of glucose production indicating that the animals were in a steady state for glucose.
Infusion of somatostatin resulted in a rapid and synchronous fall in the level of both insulin and glucagon. This finding is in agreement with earlier work carried out in vivo (21) (22) (23) (24) and in vitro (25, 26 glucagon, 2.9 for insulin) fell to approximately 1.0 within 10 min of the start of somatostatin infusion suggesting that the secretion of both hormones was quickly inhibited. After 30 min of somatostatin infusion the IRI level was at or below the sensitivity of the assay (5,uU/ml), while the IRG level ranged from 20-60 pg/ml. This residual glucagon immunoreactivity in all probability represents interfering factors in plasma which cross react with the 30K antibody (50, 51) . The conclusion that the drop in the IRG level represents for the most part a fall in "true" plasma glucagon is supported by the recent report that plasma taken from a somatostatin treated dog was devoid of "true" glucagon (mol wt 3,500) but still contained a normal amount of other materials which cross reacted with the 30K antibody (52) . The biological activity of this remnant material remains to be determined. If it is shown to have glycogenolytic or gluconeogenic activity, then the role of "true" glucagon in the regulation of glucose production is determined in this study may underestimate the overall role which all glucagon related material plays in control of glucose homeostasis. The fact remains, however, that infusion of somatostatin in the present studies, resulted in a rapid and pronounced deficiency (but not necessarily complete lack) of both insulin and glucagon. After cessation of somatostatin infusion the concentrations of both insulin and glucagon rebounded quickly. The rapidity of the reversal attests to the short biological half life of somatostatin. The explanation for the somewhat larger rebound in glucagon may lie in the prevailing hypoglycemic stimulus which was present when the somatostatin-induced inhibition was withdrawn. It may have been accentuated by the possibility that hormone accumulated in the pancreas during the somatostatin infusion period.
The success of the replacement of pancreatic hormone secretion by intraportal insulin and glucagon infusion was demonstrated both by the level and the stability of the resulting hormone concentrations. Since glucagon and insulin were infused at their normal physiological site and at rates which maintained their plasma concentrations it was possible, by assuming their extraction had not changed, to estimate the secretion rate of each hormone. In the case of insulin, this was about 400 ,U/kg per min, a value in agreement with earlier work (53, 54) . Recently Fischer et al. (54) , by using direct A-V difference measurements in the postabsorptive dog, showed that the basal secretion rate of insulin was 392 AU/kg per min. The basal secretion rate of glucagon, on the other hand, has not been as clearly assessed but it would appear from the present study that it is about 1 ng/kg per min in the postabsorptive state. This figure is similar to that suggested by Marliss et al. (55) who measured the A-V difference across the pancreas and by Iversen (56) who measured the rate of glucagon secretion by the perfused dog pancreas. After termination of the replacement infusion of either hormone the plasma concentration of that hormone remained relatively unaltered. This was presumably because the fall in the level of exogenously derived molecules was balanced by the increase in the concentration of endogenously derived hormone.
The potency of glucagon's effect on glycogenolysis and gluconeogenesis is well known (12, 32) but its physiological importance in the regulation of these processes is less clear, Mobilization of the hormone during arginine infusion, an analogy to protein ingestion, has recently been shown to be essential in preventing aminogenic hypoglycemia (48) . In addition, it is now known that somatostatin-induced glucagon deficiency is associated with a drop in the glucose level despite coexistant insulin lack, suggesting that glucagon might be important in maintaining the basal rate of glucose production (57) . The present study clearly demonstrates that such is the case and quantitates the importance of the hormone.
Hepatic glucose output fell markedly whenever glucagon secretion was inhibited, whether or not a fall in insulin accompanied the glucagon deficiency. It is now known that the presence or absence of insulin determines the duration of the depression of glucose production rather than the magnitude of the drop.3 Restoration of the glucagon level resulted in an immediate increase in the rate of glucose production. Furthermore, when basal glucagon levels were maintained by intraportal replacement of the hormone during somatostatin infusion the fall in glucose production failed to occur. A somatostatin-induced deficiency of both pancreatic hormones has previously been linked to a drop in glucose production in baboons (23) , suggesting that the importance of basal glucagon in regulating glucose output is not limited to the dog. Nor is the importance of glucagon dependent upon anesthesia, since we observed a significant drop in glucose production (28+4%, P < 0.01, n = 7) in conscious dogs given somatostatin (data not shown) as did others (58) . It is worth noting that prolonged administration (i.e. for greater than 60 min) of somatostatin alone does not result in a sustained decrease in glucose production (58) . This finding is consistent with observations made in our laboratory in experiments in which the peptide 3Liljenquist, J. E., et al. Manuscript in preparation.
was infused for 5 h. The rebound in glucose production, however, was found to be dependent on insulin lack. 4 The ability of insulin to inhibit glucose output by the liver both in vivo (7, 8) and in vitro (6, 9) is clearly established but its importance in basal amounts has not been defined. The present study clearly shows that specific inhibition of basal insulin secretion in the overnight fasted dog resulted in a significant in-crease in glucose production. This overproduction of glucose was totally abolished when the insulin level was allowed to return to normal and did not occur when the insulin level was maintained by means of an intraportal infusion during somatostatin treatment. The findings of the present study are in accord with those of Vranic and Wrenshall (59) who showed that cessation of intraportal insulin replacement in pancreatectomized dogs caused a 40% increase in glucose production.
Although not known at the time, it is now apparent that such animals had normal glucagon levels (19, 48) and it seems likely that this increase in glucose production was glucagon induced. The inability of basal amounts of insulin to further inhibit the rate of gltucose production during periods of acute glucagon deficiency is in line with in vitro data which suggest that effects of the hormnone on unstimulated processes are difficuilt to detect (4, 12) .
The present experiments show that somatostatiin has no acute effects on glucose turnover other than those attributable to its modification of pancreatic hormone secretion. This is evident from the observation that the mean rates of glucose production and utilization were unchanged during somatostatin infusion when the insulin and glucagon levels were maintained by intraportal infusion. Such a conclusion is further supported by experiments, carried out with perfused rat hind quarters and isolated rat adipocytes in which somatostatin (10-10,000 ng/ml) had no effect on basal or insulin stimulated glucose uiptake.5 Similar findings were reported in other skeletal muscle preparations (60, 61) . It has been suggested that somatostatin (70 ng/ml) interferes with the ability of glucagon to stimulate glucose production by isolated hepatocytes (62) ; however, experiments with rat liver slices failed to support this conclusion (24) . Studies from our laboratory in which isolated rat liver parenchymal cells were used have shown that somatostatin (10-1,000 ng/ml) had no effect on basal or glucagonstimulated glucose production and failed to modify the effect of glucagon (0.1-0.5 nM) on the acumulation of intracellular cyclic AMP or on the activation of cyclic AMP-dependent protein kinase.5
The data from the present experiments support the hypothesis that glucagon plays a significant role in I Cherrington, A. D., et al. Manuscript in preparation. 5 
